The U.S. Food and Drug Administration has approved Pfizer's next-generation vaccine, Prevnar 20, aimed at preventing pneumococcal disease in children and adolescents aged six weeks to 17 years. The vaccine offers expanded protection compared to the widely used Prevnar 13 by targeting seven additional serotypes of the bacteria responsible for these infections.

Pneumococcal disease can cause serious infections throughout the body, including pneumonia in the lungs. In addition to general disease prevention, the newly approved shot is authorized to help prevent a common type of ear infection known as otitis media in infants and toddlers up to five years old.

The FDA's decision follows clinical studies demonstrating that the safety and tolerability of the new vaccine are comparable to the previous version. This advancement provides healthcare providers with an enhanced tool to protect younger populations.